Oxcia AB presents positive effects of OXC-201 in lung tissue from patient with Idiopatic Pulmonary Fibrosis
Oxcia presents new preclinical data on OXC-201 at the 7th IPF summit in Boston, September 19-21 and European Respiratory Society (ERS) International Congress 2023 September 9–13. Lung tissue from IPF patients express high levels of several fibrotic biomarkers. Treatment with clinically relevant doses of OXC-201 demonstrated robust dose-dependent reduction of a number of the most important fibrosis-related biomarkers such as TGF-ß and collagen. These data correlate well with results from previous preclinical models, supporting OXC-201 as a potential treatment for IPF. Christina